Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea

Journal of Urology

Volumn 168, Issue 6, 2002, Pages 2483-2485

  Martin, David J ^a   Badwan, Kal ^a   Parker, Marilyn ^a   Mulhall, John P ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Administration; Penile induration; Penis; Topical; Verapamil

Indexed keywords

VERAPAMIL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DETERMINATION; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; ERECTILE DYSFUNCTION; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; PENIS; PENIS PROSTHESIS; PEYRONIE DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SKIN PENETRATION; TRANSDERMAL DRUG ADMINISTRATION; TUNICA ALBUGINEA;

EID: 0036895185     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64173-0     Document Type: Article

References (25)

1. Lindsay, M. B., Schain, D. M., Grambsch, P., Benson, R. C., Beard, C. M. and Kurland, L. T.: The incidence of Peyronie's disease in Rochester Minnesota, 1950 through 1984. J Urol, 146: 1007, 1991
2. Schwarzer, U., Klotz, T., Braun, M., Wassmer, G. and Englemann, U.: Prevalence of Peyronie's disease: Results of an 8, 000 man survey. J Urol, suppl., 163: 167, abstract 742, 2000
3. Devine, C. J., Jr., Jordan, G. H. and Schlossberg, S. M.: Surgery of the penis and urethra. Peyronie's disease. In: Campbell's Urology, 6th Ed. Edited by P. C. Walsh, A. B. Retik, T. A. Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., vol. 3, chapt. 83, pp. 3011-3021, 1992
4. Weidner, W., Schroeder-Printzen, I., Weiske, W.-H. and Vosshenrich, R.: Sexual dysfunction in Peyronie's disease: An analysis of 222 patients without previous local plaque therapy. J Urol, 157: 325, 1997
5. Gelbard, M. K., James, K., Riach, P. and Dorey, F.: Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol, 149: 56, 1993
6. Scardino, P. I. and Scott, W.: The use of tocopherols in the treatment of Peyronie's disease. Ann NY Acad Sci, 52: 390, 1949
7. Zarafonetis, C. J. D. and Horrax, T. M.: Treatment of Peyronie's disease with potassium para-aminobenzoate (POTABA). J Urol, 81: 770, 1953
8. Ralph, D. J., Brooks, M. D., Bottazzo, G. F. and Pyror, J. P.: The treatment of Peyronie's disease with tamoxifen. Br J Urol, 70: 648, 1992
9. Akkus, E., Carrier, S., Rehman, J., Breza, J., Kadioglu, A. and Lue, T. F.: Is colchicine effective in Peyronie's disease? A pilot study. Urology, 44: 291, 1994
10. Ahuja, S., Bivalacqua, T. J., Case, J., Vincent, M., Sikka, S. C. and Hellstrom, W. J.: A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl, 20: 444, 1999
11. Winter, C. C. and Khanna, R.: Peyronie's disease: Results with dermo-jet injection of dexamethasone. J Urol, 114: 898, 1975
12. Levine, L. A.: Treatment of Peyronie's disease with intralesional verapamil injection. J Urol, 158: 1395, 1997
13. Lee, R. C. and Ping, J. A.: Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res, 49: 463, 1990
14. Fitch, W. and Easterling, W. J.: Topical verapamil, trifluoperazine and magnesium sulfate for Peyronie's disease. Int J Impot Res, 13: S62, 2001
15. Devine, C. J., Jr., Somers, K. D., Jordan, G. H. and Schlossberg, S. M.: Proposal: Trauma as the cause of the Peyronie's lesion. J Urol, 157: 285, 1997
16. Ralph, D. J., Mirakian, R., Pryor, J. P. and Bottazzo, G. F.: The immunological features of Peyronie's disease. J Urol, 155: 159, 1996
17. El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R. and Lue, T. F.: Peyronie's disease is associated with an increase in transforming growth factor-β protein expression. J Urol, 158: 1391, 1997
18. Mulhall, J. P., Thom, J., Lubrano, T. and Shankey, T. V.: Basic fibroblast growth factor expression in Peyronie's disease. J Urol, 165: 419, 2001
19. Devine, C. J. J., Jordan, G. H. and Somers, R. D.: Peyronie's disease: Cause and surgical treatment. AUA Today, 2: 1, 1989
20. Somers, K. D., Sismour, E. N., Wright, G. L., Jr., Devine, C. J., Jr., Gilbert, D. A. and Horton, C. E.: Isolation and characterization of collagen in Peyronie's disease. J Urol, 141: 629, 1989
21. Jewelewicz, R.: New developments in topical estrogen therapy. Fertil Steril, 67: 1, 1997
22. Kalia, Y. N., Merino, V. and Guy, R. H.: Transdermal drug delivery. Dermatol Clin, 16: 289, 1998
23. Singh, P. and Roberts, M. S.: Iontophoretic transdermal delivery of salicylic acid and lidocaine to local subcutaneous structures. J Pharm Sci, 82: 127, 1993
24. Riedl, C. R., Plas, E., Engelhardt, P., Daha, K. and Pflüger, H.: Iontophoresis for treatment of Peyronie's disease. J Urol, 163: 95, 2000
25. Montorsi, F., Guazzoni, G., Bocciardi, A., Barbieri, L., Campo, B. and Rigatti, P.: Transdermal electro motive multi-drug administration for Peyronie's disease: A randomized, double-blind, placebo-controlled, partial crossover study. J Urol, suppl., 153: 472, abstract 973, 1995